Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients must sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice guidelines prior to participation in the trial, including medication washout and restrictions~* Diagnosis of Chronic Obstructive Pulmonary Disease and relatively stable airway obstruction: post bronchodilator 30%\<= Forced Expiratory Volume in 1st second (FEV1)\<80% of predicted normal (European Coal and Steel Community) and a post bronchodilator FEV1/Forced Vital Capacity\<0.70 at visit 1~* Male or female patients \>=40 and =\<75 years of age on day of signing consent.~* Current or ex-smokers with a smoking history \> 10 pack-years. Patients who have never smoked cigarettes must be excluded.~* Baseline Dyspnea Index score\< 8 at visit 0.~* Hyperinflation at rest, defined as Functional Residual Capacity \> 120% predicted at visit 1.~* Borg dyspnea score \>=4 at the end of 3min Constant Speed Shuttle Test at visit 2~* Perform technically acceptable pulmonary function tests (spirometry and body plethysmography) and complete multiple shuttle tests during the study period~* Inhale medication in a competent manner from the Respimat® inhaler and from a metered dose inhaler~Exclusion criteria:~* Significant disease other than Chronic Obstructive Pulmonary Disease (COPD); a significant disease which, in the investigator's opinion, may (i) put the patient at risk (ii) influence the study results or (iii) cause concern regarding the patient's ability to participate~* Clinically relevant abnormal baseline haematology, blood chemistry, in the investigator's opinion, or creatinine \>x2 Upper Limit Normal will be excluded regardless of clinical condition~* Current documented diagnosis of asthma~* COPD exacerbation in the 6 weeks prior to screening~* Diagnosis of thyrotoxicosis~* History of myocardial infarction within 6 months of screening~* Life-threatening cardiac arrhythmia (investigator judgment)~* Known active tuberculosis~* Any malignancy unless free of disease for at least 5 years (treated basal cell carcinoma or squamous cell skin cancers are allowed)~* History of cystic fibrosis~* Clinically relevant bronchiectasis (investigator judgment)~* Severe emphysema requiring endobronchial interventions within 6 months prior to screening~* History of significant alcohol or drug abuse (investigator judgment)~* Any contraindications for exercise testing~* Patients who have undergone thoracotomy with pulmonary resection~* Treatment with any oral or patch ß-adrenergics~* Treatment with oral corticosteroid medication at unstable doses or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day~* Treatment with antibiotics for any reason within 4 weeks of screening~* Patients being treated with Phosphodiesterase Type 4 (PDE4) inhibitors within 3 months of screening visit should not be enrolled and PDE4 inhibitors should not be withdrawn for the purpose of enrolling in this study~* Regular use of daytime oxygen therapy for \>1 hour per day and in the investigator's opinion will be unable to abstain from use during clinic visits~* Completion of a pulmonary rehabilitation program 6 weeks prior to screening or currently in a program~* Limitation of exercise performance as a result of factors other than fatigue or exertional dyspnea, such as arthritis in the leg, angina pectoris, claudication, morbid obesity~* Endurance time \>=12 minutes during the incremental shuttle walk test~* Oxygen saturation \< 85% (on room air) at rest or during exercise.~* Taken an investigational drug within 1 month or 6 half-lives or in case the investigational drug class is listed within the washout period specified prior to screening visit~* Known hypersensitivity to ß-adrenergics and/or anticholinergic drugs, Benzalkonium Chloride, Ethylenediaminetetraacetic acid or any other component of the Respimat® inhalation solution~* Women who are pregnant, nursing, or who plan to become pregnant while in the trial~* Women of childbearing potential not using a highly effective method of birth control~* Previously been randomized in this study or are currently participating in another study~* Unable to comply with pulmonary medication restrictions prior to randomization

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tiotropium + Olodaterol (Type: EXPERIMENTAL): Patients will receive tiotropium 5mcg + olodaterol 5mcg in a fixed dose combination once daily.
- Tiotropium (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).